Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
26/06/2025 12:03
June 26 (Reuters) - Revive Therapeutics Ltd RVV.CD: REVIVE THERAPEUTICS NEARS COMPLETION OF KEY NERVE AGENT COUNTERMEASURE STUDY WITH CANADIAN DEPARTMENT OF NATIONAL DEFENCE HIGHLIGHTING SIGNIFICANT STOCKPILING OPPORTUNITY REVIVE THERAPEUTICS LTD - BUCILLAMINE STUDY TO CONCLUDE BY SEPTEMBER 2025 REVIVE THERAPEUTICS LTD - PLANS TO EXPLORE BUCILLAMINE FOR TBI AND VIRAL INFECTIONS Source text: ID:nGNXbvnvsM Further company coverage: RVV.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure